_	
1	UNITED STATES DISTRICT COURT
2	EASTERN DISTRICT OF LOUISIANA
3 4	In Re: VIOXX PRODUCTS * MDL Docket No. 1657 LIABILITY LITIGATION *
5	* Section L *
6	* January 5, 2012 This Document Relates to All Cases *
7	* 9:00 a.m. * * * * * * * * * * * * * * * *
8	
9	MONTHLY STATUS CONFERENCE BEFORE THE HONORABLE ELDON E. FALLON
10	UNITED STATES DISTRICT JUDGE
11 12	APPEARANCES:
13 14	For the Plaintiffs: Herman Herman Katz & Cotlar, LLP BY: RUSS M. HERMAN, ESQ. 820 O'Keefe Avenue New Orleans, Louisiana 70113
15 16	For the Defendant: Williams & Connolly, LLP BY: DOUGLAS R. MARVIN, ESQ. 725 Twelfth Street N.W. Washington, D.C. 20005
17 18	Also Participating: Patrick Juneau, Esq. Elizabeth Cabraser, Esq. Dawn Barrios, Esq.
19 20	Bob Johnston, Esq. Ann Oldfather, Esq. Dorothy Wimberly, Esq. Elaine Horn, Esq.
21 22	Official Court Reporter: Toni Doyle Tusa, CCR, FCRR 500 Poydras Street, Room B-406
23	New Orleans, Louisiana 70130 (504) 589-7778
24	
25	Proceedings recorded by mechanical stenography using computer-aided transcription software.

PROCEEDINGS

(January 5, 2012)

THE COURT: Be seated, please. Good morning, ladies and gentlemen.

THE DEPUTY CLERK: MDL 1657, In Re: Vioxx Products Liability Litigation.

THE COURT: Liaison counsel, make your appearances for the record, please.

MR. HERMAN: May it please the Court, Your Honor, Russ Herman for plaintiffs.

MR. MARVIN: Your Honor, may it please the Court, Douglas Marvin for Merck.

THE COURT: This is our bimonthly status conference. It took me a longer time than usual with the committees before this conference, so I apologize for any inconvenience to the people on the phone.

I received from the parties their proposed agenda. I will take it in order. Any special master or deputy special master reports?

MR. JUNEAU: Your Honor, as Your Honor knows, there are several motions that are pending. There is no activity and I report no activity, so I actually have operated in a stand-down capacity. I'm strictly here reporting today that I'm going to maintain that status. I know that there's several matters out there that could be activated that could affect the

activity of the special master, but until that's done I plan to have no other activities.

Other than that, Your Honor, strangely enough, they are still calling. I'm sure Mr. Johnston and I will confirm, people still call you about the status of the cases, but those are just minuscule matters. There's really nothing other than that, other than the fact that there are some items that can rise up at a later date.

Kind of with that thought in mind, Your Honor, it would be my thought that unless directed by the Court, if the Court anticipates a specific function or responsibility I would perform, I would probably forego my appearance at any status conference until that issue arose and I would just be in a stand-down capacity.

THE COURT: I agree with that. Thank you very much for all of your work on this matter, Pat.

Anything on class actions?

MR. MARVIN: Your Honor, nothing new on class actions. As Your Honor knows, there's been a motion filed and the motion has been fully briefed, but there are no new developments.

THE COURT: Right. We discussed some potential for looking at a bellwether case, but that may be a little premature. I would like you all to get together on that and see what you can come up with.

MS. CABRASER: Right. Your Honor. Elizabeth Cabraser for plaintiffs. That might be something we could address a little bit more in the attorneys general conference call following this session. But, yes, there may be a way, in conjunction with an attorneys general trial, to also address some of the common fact questions that relate to consumer claims. Merck has not had an opportunity to react to that plan, and it's something that we hope to develop.

THE COURT: Great. Okay.

Any state/federal coordination?

MR. HERMAN: Ms. Barrios is here with a full report.

MS. BARRIOS: Good morning, Your Honor. Dawn Barrios for the state/federal committee.

The information that I'm going to give you, which is on a CD, is current through CTO 168. There's been no new conditional transfer order since our last status conference. We continue to update databases and remove cases and plaintiffs that have been dismissed.

Because of Ms. Oldfather's motion, our number of pending remands have increased. Your Honor did rule on Kentucky's motion to remand, so that one is now off the table and Kentucky is back to state court. We continue to have some derivative claimants that need to be dismissed, and Ms. Wimberly and I are working on those. Thank you.

THE COURT: Thank you.

Pro se plaintiffs? 1 2 MR. HERMAN: Mr. Johnston is here and will report. 3 MR. JOHNSTON: Good morning, Your Honor. Bob Johnston, 4 curator. 5 I have filed Curator Status Report 33 with the 6 Court. There is nothing really new to add. I think that 7 Mr. Juneau succinctly described the status of where we are with 8 occasional calls, some of the same interesting people that we have dealt with before, but I think things continue to move 9 10 well. With that, I have nothing else to add to the Court. 11 **THE COURT:** We are coming into a long-term 12 relationship with some of these people. They look upon you as 13 their family. 14 MR. JOHNSTON: I didn't realize it was going to 15 happen that way when I started doing this. Thank you. 16 THE COURT: Thank you. 17 Governmental actions, anything on that? 18 MR. HERMAN: Your Honor, Mr. Beisner isn't here. 19 Ms. Barrios can report. 20 MS. BARRIOS: Your Honor, Dawn Barrios again. going to have a separate status conference in the governmental 21 22 actions immediately following this status conference or at 23 10:00. Thank you. 24 **THE COURT:** The third-party payors, anything on that? 25 We have an issue of attorneys' fees on third-party payors.

MR. HERMAN: Yes, Your Honor. May it please the Court. The allocation committee is going to have a conference call tomorrow at 2:00 p.m. central. We will undertake to recommend figures for each applicant in accord with a limited fee fund. We will post all material that we have received from applicants as well as all of the applicant statements as to their entitlement to fees.

At that point, once those materials are posted -- and we hope to expedite that, Your Honor. We should be able to accomplish that within the next couple of weeks, in advance of Your Honor's next status conference, and then we will await Your Honor's direction as to how to proceed. We assume that applicants will have comments or objections and they will also be posted. Thank you, Your Honor.

THE COURT: My thinking is that when I get the recommendation and suggestion from the allocation committee, I post all of that on the Web site and give everybody an opportunity to look at it and make any objections, observations, responses that they may have. Then I will collect all of those and I will also post those. We will deal with those either by having a special master make some recommendations to me or my own review of the matter, and I will make the final decision on this situation.

I'm focused mainly on process. I want it to be fair and I want it to be open so that everybody knows what's

happening. We'll get through this hopefully much easier than the last time.

Pending personal injury cases subject to PTOs 28, 29, and 43?

MR. MARVIN: Your Honor, as Your Honor knows, since the last status conference, the Court arranged for a conference with Mr. Benjamin and with Merck to discuss cases that Mr. Benjamin holds to be set for trial. Mr. Benjamin holds the largest group of heart attack and stroke cases that remain.

Following the Court's order that established a procedure for the selection of a case, the first case to go to trial represented by Mr. Benjamin, the parties have since met and conferred. Each party has proposed three cases for workup for discovery. And then from that group of six cases, the parties will discuss, along with the Court if necessary, selection of one of those cases for trial.

THE COURT: We have to focus on the remaining personal injury cases. There are some things to do on those cases. We need some Lone Pine opportunities. We need some discovery opportunities. We need some motion opportunities. But when we get down to them, those that need to be tried, we are going to have to really decide how to go about it.

One way, of course, is the bellwether cases. I met with Merck's counsel and the plaintiffs' counsel,
Mr. Benjamin, and instructed that each of them have three cases

1
 2
 3

suggesting that will be the group of six. They will then do some discovery on those six. They will each have some strikes, and we will come up with one case in which to try from a bellwether standpoint.

In addition to bellwether cases, there are other opportunities such as summary trials, with each side getting two days to try their case. There are some other methods of doing it. We can try issues. We can try groups. Those other methods do require some agreement by and between counsel so that they are not trespassing on the Seventh Amendment.

If it gets to the point where each of those cases have to be tried, and there are 50 or 60 of them, then I have to give some thought to whether or not these cases should be sent back to the individual judges because I'm not going to be able to try 50 to 60 cases within 5, 6, 7 years. I can't do it because I have a docket here in New Orleans. If I have to go to various places throughout the country, that interferes with my workload here.

So it's harder and harder to argue efficiency with one court handling all of the cases. It might be quicker and easier and a better resolution for me to send those cases back to the 15 or 20 judges who were handling them initially, and they can get through them much faster than I can individually by having a "gavel will travel" approach.

MR. MARVIN: Your Honor, Merck also has several

motions that are noticed for hearing following the status conference. I assume those will be heard after the conference.

THE COURT: Okay. The fee allocation committee, any report on that?

MR. HERMAN: May it please the Court. Your Honor, the only pending matter is the third-party payor issue. There are no appeals. There's been no controversy since Your Honor directed distribution.

THE COURT: We had some issues with regard to the motion. Ann, do you want to bring that up now?

MS. OLDFATHER: Yes, Your Honor. Thank you, Your Honor. Ann Oldfather for plaintiffs.

Your Honor, we have filed a motion to strike or remand Merck's motion for summary judgment. Is that what the Court was referring to or is there something else?

THE COURT: Yes, that's basically it.

MS. OLDFATHER: Your Honor, just to address that briefly, Merck has filed a motion for summary judgment on the VTE cases, approximately 25 or so venous thromboembolism cases. In response to that motion, because we believe it put the cart before the scheduling horse, we have asked the Court to strike that motion and instead suggest that the Court focus on working with the parties to establish an appropriate scheduling order.

Not only is that the standard approach under the Federal Rules of Civil Procedure, but it's the tried and true

method in this Court utilized by the Court in the original round of bellwether cases, utilized now with the AGs, and utilized as every other group has come up. The Court has met with those parties and found out what kind of additional discovery needs to be made, both fact and expert discovery, and then has given the parties ample notice of the dates of which

that has to be concluded.

I acknowledge that we have had discussions in chambers and in court many times over the last several years about moving the cases along, but we have never officially put those dates out there, not only for my benefit but for the benefit of the *pro se* claimants and the benefit of other counsel who are not attending the status conferences every month. So we would urge in support of our motion to strike/remand Merck's motion for summary judgment that the Court remand the motion for summary judgment at this time. Obviously, it could be refiled at the appropriate stage of the scheduling process.

We would ask the Court to direct the parties, for our next status conference, to come prepared to submit a schedule by which plaintiffs' counsel and Merck believe that fact discovery can be completed in these other pending personal injury cases, dates by which experts can be disclosed, dates by which summary judgment motions, which may first be *Daubert* motions, should be filed.

Incidentally, Your Honor, I would just observe that we skipped over the part of the agenda that deals with Merck's motion to dismiss for prejudice against Ken Novick for failure to file a *Lone Pine* report. The *Lone Pine* requirement is the requirement the Court put in place back in 2007 for a report that -- for me to take the risk of paraphrasing the Court -- was meant to simply show that there was some relation between the plaintiffs' claimed injuries and Vioxx.

The Court made it clear on the record in hearings in 2008 that the *Lone Pine* report was not meant to serve as a substitute for *Daubert* caliber proof, or proof even sufficient to get past a Rule 56 motion, but it was some initial showing that this wasn't just a rash that might have been caused, for example, by something else.

So Merck has stated -- and I would appreciate if this was just confirmed on the record -- that it is going to withdraw its motion to dismiss as to Dr. Novick for failure to comply with the *Lone Pine* requirements because he has submitted a report from an expert that we believe was sufficient for *Lone Pine*.

Merck has stated its intent to convert that to a Rule 56 motion. As with my earlier comments, I think Dr. Novick should have the benefit of a scheduling order, the benefit of an opportunity to know the dates, we as his counsel to know the dates by which we need to be prepared to submit our

proof to Rule 56 caliber review by the Court.

So we would urge the Court to strike or remand Merck's motion for summary judgment at this time. At the very least, failing all of that, I am going to ask the Court if we can change the January 18 submission date in the event that it needs to be argued. Thank you, Your Honor.

THE COURT: Let me hear from you.

MR. MARVIN: Your Honor, first on the motion that we filed to dismiss the cases that allege a venous clot, the venous thrombosis cases, that motion is not at all premature. It was filed two years after this Court directed the PSC, for which Ms. Oldfather is liaison counsel, to marshal the issues regarding general causation. So there's been plenty of opportunity for discovery to be conducted and, indeed, discovery has been conducted. Millions and millions of pages have been produced. They're sitting in the plaintiffs' depository.

The burden now is on the plaintiffs to come forward to show there's some disputed fact that would preclude the grant of the motion for summary judgment, and that obviously has not been done yet. In our opposition to the motion, we submitted a schedule to the Court that we would propose for teeing up this issue, which is a threshold issue.

In fact, what we have proposed is that the plaintiffs be given another three months to develop an expert,

if they can, and if that expert can then go ahead and file a report to put in issue as a disputed fact any of the issues on which Merck moved. If the plaintiffs cannot produce that expert by three months from now, then the motion should be granted.

If instead plaintiffs do come forward with an expert report, then we suggest that the traditional approach be followed. We would go ahead and file our expert report in response. There could be 60 days, for example, for expert discovery, and at that time we would propose to file our motion for *Daubert*. The case could then proceed as the Court directs once those motions are filed.

Right now, what's pending is this motion for summary judgment. As I say, there is a burden on the plaintiffs to show that there's a disputed fact. They haven't done so. While we are not adverse to giving them additional time to do it, we ask that a schedule along the lines that I suggest be put in place so that this issue can be teed up.

THE COURT: Do you want to respond?

MS. OLDFATHER: Thank you, Your Honor. Judge, this isn't a generic "dispute of fact" motion for summary judgment. This is a motion for summary judgment where Merck has just, at the very end of October, for the first time put in the record two expert reports for previously nondisclosed experts, where these two physicians expressed the opinion that there is no way

that Vioxx can cause a VTE. This is a very significant scientific conclusion that these two physicians are attempting to advance. They have not been previously disclosed. They weren't disclosed in answer to any pending maybe master template interrogatories that had been issued earlier by the former PSC.

This motion, Your Honor, goes to -- I don't have the exact count with me because I didn't bring the motion for summary judgment since it's not teed up today, but it goes to approximately 30 different claimants represented by different counsel and some of whom are *pro se*. Our role as the PSC for this group and as liaison for this group is to coordinate and to develop. There has not been a time where our cases, this group of cases has moved to the front and has had the deadline set.

This Court has gone through this litigation very methodically and focused on each group of cases and you have given each group specific deadlines. They have known it was coming too. They got the benefit of more than -- Mr. Marvin suggests three months from today that we are supposed to have all this done in 30 different cases with -- I don't know the exact count of different counsel and different pro se claimants.

We don't oppose the fact that these cases do need to be brought to a conclusion. Deadlines are needed, but

under Rule 26, deadlines aren't set like this. We would ask the Court for a legitimate amount of time to get the cases developed and submitted on Rule 56 motions, if then they are going to be filed.

Three months is not sufficient, but I would like an opportunity to go back to the repository to see what kind of adverse event reporting is present on these types of injuries because I am not aware of it being as extensive as it was described in chambers. I had thought the facts database discovery was limited to some random sampling out of the facts database, and I might be wrong, but obviously this is something that we have known we have to develop. We just haven't done it yet, and it has to be done in order for experts to reach a conclusion about mechanism.

THE COURT: I understand the issue. This is the way I see it. I'm focused at this point on those cases from a Lone Pine standpoint. I got this MDL in 2005, so I have had it now for six years. The states have had it maybe about three or four years before I got it. So we are moving on one decade now in this particular litigation. It seems to me that it's appropriate and it's not offensive or high-handed for a court to require that the litigants who make complaints be required to produce a Lone Pine report. This type of report, as I mentioned before, is not looked at as an inclusive report to withstand a Daubert motion but it is a preliminary report.

These cases are "other injury" cases. The "other injury" cases involve various complaints.

There's been, almost 10 years now, in this litigation a lot of discovery. As I have said before, I have tried at least six of these cases. The state courts have tried another seven or eight of the cases. We have had millions of documents discovered, thousand of depositions, depositories arranged, categorized, trial plans worked up, and we are at the point now where it's not inappropriate to require a claimant who says that he or she has certain complaints to have a doctor say those complaints are related to the ingestion of Vioxx. If they can't do that, then they don't have a case.

expenses are taken, you ought to find out whether or not there is any science at all to justify it. Now, it seems to me the appropriate way of doing it is for the attorneys to go to the depository and look at it, get information and give it to their doctors. If they can't get a report from a doctor that says this complaint is related to Vioxx after 10 years, then it's appropriate to end that case. If they say it is related, then you go to the next step. That doctor then is deposed and then that doctor is "Daubert-tized." If he withstands Daubert, then the motion for summary judgment is not justified and the case is tried.

I don't think we want to discover these cases

the way that it has required discovery in every case before you know whether or not there is a case. It doesn't make any sense to me. You're going to spend more per case only to find out that you don't have a case. I don't understand how that works.

MS. OLDFATHER: Judge, I'm sorry. I wasn't clear about this. The clients whom we represent have filed *Lone Pine* reports. They are not yet of the caliber that would withstand *Daubert* or Rule 56 because they haven't been worked up to that extent because we are now at what you just outlined --

THE COURT: Do you have *Lone Pine* reports for these particular cases?

MS. OLDFATHER: Yes, they do.

MR. MARVIN: Your Honor, we do have *Lone Pine* reports in these cases. But as Ms. Oldfather says, they don't address general causation, which is the threshold issue here; namely, as to whether Vioxx can even cause a VTE.

THE COURT: That, to me, is really where we need to be. Then if they say it is, it just seems to me then you go to the next step. If they say it is not, why do you go to the next step?

MS. OLDFATHER: Well, the first step, the Lone Pine reports, they have said it is caused by Vioxx, and we have studies that indicate that VTEs can be caused by Vioxx. We have to get them up to the caliber now where they will survive Daubert and Rule 56, which brings us to the step Your Honor is

1
 2
 3

outlining, which is now go to the repository, get all of the scientific proof that will rebut the charges and the attacks that are going to be made by Merck.

So it's maybe not as grim as Your Honor thought it was, but there is a bunch of work. You're absolutely right about that. If we have the opportunity now to talk about the scheduling, I'm going to follow up with Mr. Herman's comments in chambers about the -- and I agree the repository has always been available, but I'm now going to work directly with them to see what they have on VTEs. In any event, we are ready to go to that next step. We have not gotten teed up to the degree that the prior cases have.

THE COURT: Have you taken depositions of the doctors --

MS. OLDFATHER: Some have, yes.

THE COURT: -- who have given the reports?

MR. MARVIN: Some, yes, Your Honor.

MS. OLDFATHER: They have given jury survivable causation testimony as long as it survives *Daubert*. But again, I know what Your Honor is going to look for in *Daubert*, and I would like to get it to that standard so that we can address the arguments that Merck has just presented us with and the kind of coming out of the off-course motion for summary judgment that we are just not prepared to deal with at this point, Judge. For all the reasons you indicated, we are not

prepared to deal with it.

MR. MARVIN: Your Honor, I just want to point out that the Court has addressed this issue in PTO 46 that was entered August 20, 2009, more than two years ago. The Court directed Ms. Oldfather's committee to, quote, marshal issues regarding general causation. So it's been more than two years since the Court has given that direction.

We filed our affidavits setting forth our experts' views that there is no evidence to support any general causation or any link between Vioxx and VTEs. We filed those in October. So the PSC, too, has had this direction since August 2009, and it's had our expert reports since October. We just think it's time now for them to come forward and see if they really do have a case.

THE COURT: We will continue the motion. Let me continue it presently until our next status conference, which is April 1. I'll meet with the parties before then. I will set a status conference for this case sometime in March with counsel. I can do it on the phone, but I do want to keep on top of this, and we'll see where we are in March.

Meanwhile, Ann, you're going to have to go to the depository and get materials and give to it your doctors. Let's see where we are with these cases.

MS. OLDFATHER: Absolutely, Your Honor.

THE COURT: We have been a long time on these cases,

1 honestly.

MS. OLDFATHER: Judge, on the scheduling, just so the Court knows, I received a letter from Mr. Beisner right at the end of the year about Merck's desire to take a preservation deposition from Dr. Briggs Morrison. Obviously, we are moving forward. That's been set for two days in March, March 8 and March 9. That's going to be a huge job getting ready for that. I'm simply suggesting that in terms of our being ready for a status conference and having a meaningful discussion with the Court about what we have learned -- and it's hard for me to see much difference between after March 8 and April 1 and April 1 itself, so I would be lobbying for April 1 for our status conference too.

MR. HERMAN: May it please the Court. I have been often called a jester or a fool, but I think April 1 is a Sunday.

THE COURT: It is.

MS. OLDFATHER: What a good idea.

THE COURT: I'm told that the day is March 1. How's that for you-all?

MS. OLDFATHER: We would probably still be -- it
would be premature. I think after the Morrison deposition --

THE COURT: The next one is going to be --

MS. OLDFATHER: Unless we could do a special status conference on this issue around mid March, whatever the Court

pleases.

MR. MARVIN: Your Honor, do we really have to wait that long to set a schedule for our motion?

MS. OLDFATHER: Well, I would like to have a chance to get into the repository and do all of the things that we are talking about to have meaningful knowledge of what time we are going to need.

THE COURT: Rather than hold up everybody, let me talk with you-all right after the conference and I will deal with it. I do have to move this case, though.

MS. OLDFATHER: Thank you, Your Honor.

MR. MARVIN: Your Honor, if I just may raise this one issue for the Court's consideration as well. Our motion was directed at 28 plaintiffs. Ms. Oldfather responded on behalf of 11, so there's been no opposition by 17 of the plaintiffs and the time has passed for that. So what we would ask --

THE COURT: What's the situation with those 17, Ann? You don't represent them?

MS. OLDFATHER: No, I don't represent them, Your Honor. I imagine they are waiting to see the ruling on the motion to strike or remand because that would benefit them also. They are entitled to the same scheduling notice as everyone else.

THE COURT: I'm denying the strike. I'll take those
17. Let me decide what to do with those. Give me a list of

1 the 17 that haven't responded.

MR. MARVIN: Thank you, Your Honor.

MS. WIMBERLY: Your Honor, Dorothy Wimberly for Merck.

Ms. Oldfather mentioned the Kenneth Novick motion. I had thought we were going to address those at the end of the conference.

THE COURT: Why don't we do that right now. This is just about the end.

MS. WIMBERLY: Your Honor, Ms. Oldfather did correctly state she has now assumed representation of Kenneth Novick, and she filed a notice of compliance and argues that he is now in compliance. We are not going to argue about that. We do disagree with that, but we do hereby withdraw the motion without prejudice, which was Record Document 40199, which was for failure to submit a *Lone Pine* report.

We do intend, as Ms. Oldfather stated, to file a motion for summary judgment, a Rule 56 motion. She said something about needing a scheduling order. Your Honor, we have filed dozens of Rule 56 motions directed to individual plaintiffs whose discovery and reports are simply not sufficient and don't validly state a claim, and that's the motion we are filing. There is no scheduling order or anything like that that's needed. We will be getting that on file in the near future and believe it should be ripe for hearing at

1 the next status conference.

Your Honor, we had also, subject to Record Document 40199, a *Lone Pine* motion, one additional plaintiff. I would point out to the Court that this *Lone Pine* motion was filed in April of 2010. It was deferred as to a number of plaintiffs such as Mr. Novick and the other last plaintiff, Richard Garcia, to enable pending motions to withdraw to be granted. Those motions were granted. This motion has been renoticed for hearing. It was served on Mr. Garcia. We have received no response. It has now been rolled over numerous times, and we would ask the Court to grant the motion as to Mr. Garcia and to dismiss his case with prejudice for failure to provide a *Lone Pine* report.

THE COURT: He is the one that had a lawyer and now doesn't have a lawyer?

MS. WIMBERLY: Doesn't have a lawyer, hasn't had one for months and months, and has provided no response.

THE COURT: Okay. I will grant that motion.

MS. WIMBERLY: Then we had one final motion that was set today. It appears on page 8. It is the last remaining plaintiff who had some issues relating to succession matters and who could sign and so forth. We had noticed it for today. That relates to Louise Young, Record Document 63105.

They have finally been able to marshal all of their descendents, and they have a state court hearing set for

So we would like to roll this one over to March 1 1 January 24. 2 for a final time. There should be a resolution in advance of 3 the next conference. 4 **THE COURT:** What are we dealing with there, Dorothy, 5 from the standpoint of the heirs? 6 MS. WIMBERLY: I think Ms. Horn is better prepared to 7 address the details, but I think they are very hopeful that 8 they will come out of the hearing on the 24th with a ruling. 9 MS. HORN: As to that particular claimant, there's 10 been a series of deaths which increased the pool of heirs. At this point in time, the array of heirs that exists is somewhat 11 12 different than when they filed the initial paperwork, so we 13 would have it resolved --14 **THE COURT:** I will take that up the next time. The 15 next time is when, March 1? March 1, not April 1. 16 Anything else other than your motion, Ann? 17 have a meeting also. Let me talk with you guys first. Doug, 18 Ann, let me see you. 19 That's the end of the conference. Thank you 20 very much. (Proceedings adjourned.) 21 * * * 22 23

2425

CERTIFICATE

I, Toni Doyle Tusa, CCR, FCRR, Official Court
Reporter for the United States District Court, Eastern District
of Louisiana, do hereby certify that the foregoing is a true
and correct transcript, to the best of my ability and
understanding, from the record of the proceedings in the
above-entitled matter.

<u>s/ Toni Doyle Tusa</u> Toni Doyle Tusa, CCR, FCRR Official Court Reporter